Day: March 14, 2023

Initiation of APEX Part 2 planned for mid-2023Updated clinical data from Phase 3 PEAK lead-in in GIST patients expected 1H23 Initial clinical data from Phase 2 SUMMIT trial in NonAdvSM on-track for 2H23Ended 2022 with $259.3 million in cash; sufficient to fund operations into 2025WALTHAM, Mass. and BOULDER, Colo., March 14, 2023 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided a business update and reported financial results for the fourth quarter and full year of 2022. “2022 was a pivotal year for Cogent marked by our promising clinical data with bezuclastinib in systemic mastocytosis, the initiation of our Phase 3 PEAK trial in GIST, and the build-out of the Cogent Research Team,” said Andrew Robbins,...

Company maintains strong cash position of $249.1 million SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the fourth quarter and year ended December 31, 2022. “2022 was an important year of progress, as we advanced both of our two lead programs, RPT193 and FLX475, in inflammatory disease and cancer, respectively,” said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics. “This progress has positioned us for future milestones in 2023, including our anticipated initiation of a Phase 2a trial...

New Business Strategy Focused on Precision Oncology LONDON and HONG KONG, March 14, 2023 (GLOBE NEWSWIRE) — Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics and precision oncology company, today announced financial results for the fourth quarter and full year ended December 31, 2022. Financial HighlightsRevenue of US$275.8 million in the full year 2022 Revenue of US$52.3 million in the fourth quarter 2022 Adjusted EBITDA of US$58.3 million in the full year 2022 Adjusted EBITDA of US$12.1 million in the fourth quarter 2022 Cash and other short-term assets1 of US$242.1 million as of December 31, 2022________________1 Represents current assets, including cash and cash equivalents and short-term deposits totaling US$166.6 million, financial assets at fair value through profit or loss of...

First cohort of Larimar’s Phase 2 dose exploration trial of CTI-1601 in participants with Friedreich’s ataxia (FA) is fully enrolled and proceeding as planned Larimar expects to provide an update on the next steps of the Phase 2 trial in Q2 2023, after the FDA and independent data monitoring committee review data from the first cohort and provide feedback to the Company Top-line safety, pharmacokinetic, and pharmacodynamic (e.g., frataxin level) data from both of the Phase 2 trial’s planned cohorts expected in 2H 2023 Cash and investments of $118.4 million at December 31, 2022 provides projected cash runway into 2H 2024BALA CYNWYD, Pa., March 14, 2023 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today...

Record Full Year Sales, Net Income and Adjusted EBITDA COLUMBUS, Ohio, March 14, 2023 (GLOBE NEWSWIRE) — Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding”, “Core” or the “Company”), a leading engineered materials company specializing in molded structural products, principally in building products, industrial and utilities, medium and heavy-duty truck and powersports industries across the United States, Canada and Mexico, today reports financial and operating results for the fiscal periods ended December 31, 2022. Fourth Quarter 2022 HighlightsNet sales of $86.4 million, up 18.1% from $73.2 million in the prior year; and product sales of $83.1 million, up 22.0% from the prior year. Gross margin of $11.5 million, or 13.4% of net sales, compared to $8.5 million or 11.6% of net sales in the prior year. Selling,...

HANGZHOU, China, March 14, 2023 (GLOBE NEWSWIRE) — Nano Labs Ltd (Nasdaq: NA) (“we,” the “Company” or “Nano Labs”), a leading fabless integrated circuit design company and product solution provider in China, today announced its unaudited financial results as of December 31, 2022 and for the three months ended December 31, 2022. Fourth Quarter 2022 Financial HighlightsNet revenue was RMB12.7 million (US$1.8 million) for the three months ended December 31, 2022, compared to a net revenue of RMB3.2 million in the same period of 2021. Gross loss was RMB76.6 million (US$11.0 million) for the three months ended December 31, 2022, compared to a gross loss of RMB23.8 million for the same period of 2021. Loss from operations was RMB136.9 million (US$19.7 million) for the three months ended December 31, 2022, compared to a loss from operations...

Focused targeted oncology pipeline advancing towards multiple near-term milestones; runway into 2025 Novel paralog-selective TEAD inhibitor, IK-930, advanced through multiple dose escalation cohorts, Fast Track and Orphan designations granted; initial clinical data planned for 2H 2023 Nominated potential best-in-class MEK-RAF complex inhibitor, IK-595; advancing towards IND in 2H 2023 Presented positive data from IK-175 Phase 1b clinical trial in urothelial carcinoma; Fast Track designation recently granted for combination with immune checkpoint inhibitors BOSTON, March 14, 2023 (GLOBE NEWSWIRE) — Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced financial results for the fourth quarter and full year ending December...

Four Data Centers Operational and Hashing at All-Time High Hash Rate Capacity of ~5.2 EH/s Completion of Initial Build Out at Odessa Data Center Expected by April 2023 GAAP Diluted Net Loss of $0.16 per Share (Non-GAAP Diluted Net Loss of $0.26 per Share) NEW YORK, March 14, 2023 (GLOBE NEWSWIRE) — Cipher Mining Inc. (NASDAQ: CIFR) (“Cipher” or the “Company”), a leading developer and operator of bitcoin mining data centers, today announced results for its fourth quarter and full year ended December 31, 2022, with an update on its operations and deployment strategy. “We are pleased to announce financial results that demonstrate our resilient position as a low-cost producer of bitcoin, while we continue our steady march toward the completion of our initial data centers,” said Tyler Page, CEO of Cipher. “As always, our focus is on...